Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6854602 | 0.89 | ATM (0.43) | HPGDLMNASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL2997519 | 0.84 | HPGD (0.46) | HPGDLMNASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL15974565 | 0.84 | HPGD (0.50) | HPGDLMNASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL20825485 | 0.82 | HPGD (0.45) | HPGDLMNASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL31332733 | 0.82 | HPGD (0.45) | HPGDLMNASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL6848139 | 0.82 | ATM (0.36) | HPGDLMNASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL2997520 | 0.77 | HPGD (0.44) | HPGDLMNASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL28164399 | 0.76 | HPGD (0.45) | HPGDLMNASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL26632843 | 0.75 | ALDH1A1 (0.49) | HPGDLMNASMN1; SMN2ALDH1A1POLB | |
| SCHEMBL22552890 | 0.75 | ALDH1A1 (0.41) | HPGDLMNASMN1; SMN2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1178031-B1 | PROCESS FOR THE PREPARATION OF ORGANIC COMPOUNDS WITH MANGANESE CATALYSTS OR THE LIKE | DAICEL CHEM (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-6548713-B2 | Efficiently producing a compound having an alkyl group or alkenyl group bonded at the alpha position of an electron attractive group, by catalytic radical addition reaction with compound of Group 5,6,7,8, or 9 | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-04-15 | — | — | US | disclosed |
| US-20020165416-A1 | Process for the preparation of organic compounds with manganese cataylsts or the like | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2002-11-07 | — | — | US | disclosed |
| EP-1178031-A1 | PROCESS FOR THE PREPARATION OF ORGANIC COMPOUNDS WITH MANGANESE CATALYSTS OR THE LIKE | Daicel Chemical Industries, Ltd. (JP) | 2002-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165416-A1 | Process for the preparation of organic compounds with manganese cataylsts or the like | SOD1, CAT, SOD3 | HPGD 2776/4885LMNA 3237/4885SMN1; SMN2 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.